Objectives. No proven treatment exists for ACPA-negative undifferentiated arthritis (UA). The aim of this study was to evaluate whether abatacept is effective in treating poor prognosis, ACPA-negative UA, including its effect on power Doppler on US (PDUS).
Introduction
An emerging aim in the management of RA is to identify patients at the pre-RA stage and intervene with immunomodulatory therapies to prevent its progression to RA. Undifferentiated arthritis (UA) is defined as an inflammatory
Patients and methods
The study was sponsored by the University of Leeds (Sponsor Ref: RR08/8686; EudraCT: 2008-004878-41), approved by the Leeds (East) Research Ethics Committee (REC reference no. 09/H1306/33) and conducted in accordance with the International Conference on Harmonization Good Clinical Practice and local regulations. All patients provided written informed consent for this ACPA Sero-negative Undifferentiated arthritis study.
Patients
Patients that satisfied the following key eligibility criteria were considered for this study: patients with UA defined as symptomatic synovitis of two or more joints (who did not meet diagnostic criteria for any other rheumatic disease); symptom duration [defined as the time from the onset of symptoms (joint pain, swelling, or significant stiffness) of UA to enrolment] of >12 weeks and 418 months; being negative for ACPA (CCP2); and US evidence of a PD-positive signal of 5 1 (in at least one of 20 joints scanned); no prior therapy with any DMARD therapy before screening; and no i.m. or IA steroid within 6 weeks prior to baseline was permitted. To minimize the risk of including self-limiting UA, particularly in the absence of autoantibodies, the PDUS criterion was included as a poor-prognosis factor of persistence [10] , thus ensuring subjects with definite, active, synovitis with likelihood of persistence of arthritis were recruited.
Study design
The study period was 24 months. Enrolled subjects received intravenous abatacept monotherapy (as per the standardized body weightbased dosing regimen of: <60 kg: 500 mg; 60100 kg: 750 mg; >100 kg: 1000 mg) for the first 12 months of the study. Abatacept was administered on days 1, 15 and 29, and every 28 days thereafter for a total of 14 doses, with subsequent 12-month follow-up. Subjects were permitted to take NSAIDs throughout the study. Single i.m. or IA corticosteroid medication could be utilized at a maximum frequency of every 3 months during the trial, at the discretion of the investigator; but was not permitted within 8 weeks of a disease activity assessment.
Subjects with persistent UA after 6 months of study medication received additional DMARD treatment at the discretion of the investigator. Subjects who developed RA at any point during the trial were discontinued from the study and allowed to receive DMARDs at the discretion of the investigator.
Laboratory analyses
The Human Leucocyte Antigen (HLA)DRB1 subtyping with HLADR 1, 4 and 10 serotypes that recognize the HLADRB1*01, HLADRB1*04 and HLADR10*1001 genes, respectively, were tested. Patients that tested positive for any of these three genotypes were assigned sharedepitopepositive status. Anti-CCP antibody levels [anti-CCP2; ImmunoCap 250 (Phadia)] were also measured, with a cut-off of <7 U/ml.
PDUS
Two rheumatologists (C.R., J.E.F.) performed blinded PDUS; both received training in our Institution that included reproducibility and reliability testing before contributing to research studies. US scanning was performed (using a GE E9 machine equipped with a 615 MHz linear transducer) to determine the presence of synovitis at baseline and at 6-monthly intervals to study completion (24 months). Specifically, grey scale (GS) and PDUS assessments, and erosions at baseline and 12 and 24 months were scored according to the OMERACT definition [14] . Bilateral wrist, knee and second to fifth MCP and PIP joints (20 joints in total) were scanned and each assigned a GS and PDUS score (maximum of 3), giving a maximum total scores of 60 for each.
Radiographic assessment
Plain radiographs of bilateral hands (carpal, MCP and PIP joints) were performed at baseline and 6, 12 and 24 months after the start of study medication to assess structural damage. Radiographs were scored as per the modified Genant-modified Sharp scoring system [15] by a single reader, with re-reading of baseline radiographs to ensure acceptable reproducibility. All time points for individual patients were viewed simultaneously but in random order and with the acquisition dates masked in order to blind the reader to chronology.
Patient-reported outcomes
Assessments to determine self-reported functional status (Disability Index of HAQ), health status (EQ-5D) and health-related quality of life were undertaken at the following time points: 3, 6, 12, 18 and 24 months following the start of open-label abatacept.
Statistical analysis
This was a proof-of-concept, open-label study. All available data from all subjects who received at least one infusion of study medication at any time were included in the safety and efficacy analyses, unless otherwise specified.
The primary outcome of the study was the proportion of subjects that at 6 months achieved DAS44 remission (DAS44 <1.6), had a maximum of one swollen joint for at least 3 consecutive months and had no radiographic progression (defined as change that did not exceed the smallest detectable difference) over the first year.
Secondary efficacy outcome measures included the proportion of subjects that achieved: DAS44 remission, DAS28 remission, ACR remission and modified remission, and the mean DAS28 and Persistent Inflammatory Symmetrical Arthritis (PISA) score at 3, 6, 12, 18 and 24 months. Spearman's rank correlation (rho) was used to explore for an association between baseline PDUS score and DAS44 remission.
Adverse events (AEs) and serious AEs (SAEs) were summarized as the total number of events and number of unique events (with recurring events summarized per patient as the most severe occurrence of that event).
Handling of missing data
Screening values were imputed for missing baseline values. Patients who withdrew due to lack of efficacy were considered non-responders for the primary end point. Patients with missing data for an individual variable at any visit (with the exception of the 6-month visit) were excluded from the analysis of that variable at that visit.
Results

Baseline characteristics
Twenty-three patients were screened, of which the target 20 patients were enrolled. One subject who was negative for ACPA prior to screening had a positive titre at screening and was inadvertently included, constituting a protocol violation. The data were analysed twice: the first analysis included all 20 patients, then it was repeated with this subject excluded. The other baseline characteristics and outcome of the analyses did not differ significantly. Results from all 20 are thus presented (and the analyses with the CCP-positive subject excluded are available in the supplemental file; Tables S1S5, available at Rheumatology Online, corresponding to Tables 15 in this report). Baseline characteristics are summarized in Table 1 . At the time of study protocol development and patient recruitment, the 2010 RA classification criteria [16] had not been established. Retrospectively applying these criteria to our cohort, nine patients would satisfy the criteria for RA classification.
Missing data
An ESR that was unavailable at 12 months for one subject and 18 months for another was imputed using a published nomogram [17] for converting CRP to ESR.
Withdrawals
Two patients withdrew after 6 and 12 months for an AE and SAE (see AEs later). A further three subjects were lost to follow-up after 12 months (reasons unknown).
Primary end point
Only 2/20 (10%) subjects achieved the composite primary endpoint (DAS44 remission, a maximum of one swollen joint for at least 3 consecutive months and no radiographic progression defined) at 6 months.
Evaluating the individual components, the majority, 15/ 18 (83%; 95% CI: 61, 94%) had no radiographic progression (baseline radiograph missing in 1 and follow-up radiographs missing in 2) and 12/20 (60%; 95% CI 39, 78%) had a maximum of one swollen joint or less for at least 3 10 (423) a One subject that was negative for ACPA prior to screening had a positive titre at screening and was inadvertently included. This was not the same patient who was RF positive (which was not an exclusion criterion). b HLADR 1, 4 and 10 serotypes that recognize HLADRB1*01, HLADRB1*04 and HLADR10*1001 genes, respectively, were tested. Patients that tested positive for any of these three genotypes were assigned SE-positive status. Sample not taken (n = 1); incorrect sample sent for processing (n = 1). n/N: denotes number of subjects positive for the characteristic/total number of subjects; RF, positive >20 m/ml; SE: shared epitope; TJC: tender joint count; SJC: Swollen joint count; GS: grey scale; PDUS: power Doppler US.
consecutive months. Only 6/20 (30%; 95% CI: 15, 52%) subjects achieved DAS44 remission. Table 2 details the clinical efficacy variables over the 2-year study period.
Secondary end points
Clinical outcomes
Persistent synovitis
At 6 and 12 months, 25% (5/20) and 32% (6/19) patients, respectively, demonstrated persistent clinical synovitis (two or more tender and swollen joints).
Disease activity scores and remission rates
Reduction in mean (S.D.) DAS44/DAS28 was observed from baseline values of 2.66 (0.77)/4.26 (1.13), respectively, to 2.01 (0.81)/3.07 (1.26) at 6 months; with further notable reduction to 1.78 (0.95)/2.64 (1.19) at 12 months, respectively.
At 6 months, DAS28 remission was achieved in 6/20 (30%; 95% CI: 14.5, 52%). At 12 months, DAS44 and DAS28 remission rates (withdrawal visit data from $9 months imputed for one patient) were observed in 8/20 (40%; 95% CI: 22, 61%) and 10/20 (50%; 95% CI: 30,70%) subjects, respectively.
PISA score
At baseline, 9/20 (40%) of patients had a PISA score of 53, consistent with poor prognosis; this was reduced to 7/19 (36.8%) at month 6 and 6/19 (37.5%) at both months 12 and 24.
Changes in individual DAS components 
PDUS findings
A striking decrease in the median (IQR) total PDUS score was noted from 10 (423) at baseline to 3 (212) and 3 (05) at 6 and 12 months, respectively. A more modest reduction in the median (IQR) total GS score was recorded; 30 (1840) at baseline, 22 (1632) at 6 months and 19 (1229) at 12 months. This was mainly attributable to reduction in the median (IQR) total number of joints with GS >1 [from 10 (615) to 7 (612) and 7 (510) at baseline, 6 and 12 months, respectively (Table 3 ). The median (IQR) number of joints with GS >1 and PDUS >0 at baseline was 5 (211), and this was reduced to 2 (15) and 1 (03) at 6 and 12 months, respectively (the results are detailed in Table 3 ). Table 4 details the maximum GS and PDUS scores by each joint site. The wrist joint was the most resistant to reduction in GS and PDUS. All patients had a GS of two or more in the wrist at baseline and 12 months. One patient achieved a GS of 0 by 24 months. A reduction in wrist PDUS score was observed in a small proportion. At baseline, 45% (9/20) and 25% (5/20) had PDUS of two and one, respectively, in the wrist; with 32% (6/19) and 37% (7/19), respectively, by 12 months. In contrast, notable reductions in both GS and particularly PDUS were seen 
Analysis of PDUS by joint site
Baseline PDUS and DAS44 remission
There was no evidence of an association between baseline PDUS score and change in DAS44 (Spearman's r = À0.16, n = 19). Baseline PDUS score was slightly lower in those who achieved DAS44 remission at 6 months [median (IQR) 9 (314), n = 6] than in those who did not [12 (523) , n = 13].
Radiographic progression
The re-read of baseline radiographs for reproducibility was excellent (ICC = 0.98 [0.950.99]). The mean and median joint space narrowing, erosion and Genant-modified Sharp scores at baseline, months 6, 12 and 24 are presented in Table 5 . Of note, 18/20 patients had baseline radiographs, with only half the patients having repeat evaluation at month 24. Median joint space narrowing and erosion scores remained unchanged throughout. Mean and median total modified Sharp scores remained stable throughout the study period.
Additional medication
None of the patients were prescribed oral steroids within the first 12 months, and no additional synthetic DMARDs were commenced in the first 6 months of the study, in line with the study protocol.
Months 06
One patient received an IA shoulder injection at week 11 by their GP, which constituted a protocol violation.
Months 612
One patient received two IA injections (80 mg depomedrone each time) for a Baker's cyst/right knee effusion at weeks 25 and 28. Two patients required synthetic DMARDs within the first 12 months; one subject was prescribed MTX (20 mg weekly) at week 32 and withdrew 3 weeks later, and the second received HCQ (400 mg daily) at week 29.
Months 1224 following abatacept cessation
Ten patients received synthetic DMARDs after abatacept was stopped at 12 months. Seven of these were prescribed MTX (one of whom was the subject already taking HCQ, prescribed at week 29 as indicated above) and the other three received HCQ.
Outcomes following cessation of abatacept
Disease activity outcomes
By 24 months, 47% (7/15) of patients with evaluable data had persistent clinical synovitis. Following cessation of abatacept, small increases in DAS44/28 values were observed, but with a plateau at 24 months (similar values to those seen 6 months into the study). The DAS44 and DAS28 remission states were broadly maintained at 18 and 24 months (see Table 2 ). The CRP reduction described above in the first year was maintained throughout the follow-up time points; as were joint counts (Table 2) .
AEs
There were no serious AEs during the first 12 months. Subsequent to abatacept cessation, one patient was diagnosed with an upper right lobe lung tumour shortly after the 12-month infusion. This SAE was thought to be unrelated to the study medication. Surgery to remove the tumour was successful. There were no infections requiring i.v. treatment/hospitalization and no abnormal liver enzyme tests. Another patient was found to be neutropaenic at 1300/mm3 after starting MTX. In total, there were 131 AEs (including 102 unique AEs) during the course of the 2-year study. These are detailed in Table 6 .
Discussion
This proof-of-concept, open-label study is the first to evaluate the scope for biological immunomodulatory therapy in poor-prognosis, ACPA-negative UA, an important but understudied group. The findings suggest abatacept monotherapy confers clinical improvement in poorprognosis, ACPA-negative UA and demonstrates the ability of abatacept to reduce the PDUS signal. ACPA-negative UA, when persistent, is also associated with functional impairment and erosive damage [18] . We have previously demonstrated the utility of PDUS in identifying persistence in seronegative disease [10] . Studies to date in an UA patient group have been relatively limited, although an earlier study in early oligoarthritis by our group demonstrated that disease-modifying intervention (IA corticosteroid and SSZ) reduced clinical synovitis [19] . The PROMPT study failed to indicate any benefit of MTX in seronegative UA on any outcome (preventing the development of RA, the signs and symptoms or radiographic progression) [12] . Thus, there is a lack of effective therapies in this group. The ADJUST study suggested abatacept could delay progression from ACPA-positive UA to RA [11] . These observations stimulated the basis for this study in a similar ACPA-negative group, with a proof-of-concept study designed to support our hypothesis before embarking on a larger, randomized study. Interestingly, almost two-thirds of our cohort was shared-epitope positive, and half of those tested positive for HLADRB1*0401, which confers the highest risk in predisposition to anti-CCP antibodies [20] . The basis for this remains unclear.
A three-composite primary end point (encompassing clinical, disease activity composite and radiographic components) was chosen to acknowledge the modern expectations of treatment of inflammatory arthritis. A low proportion (n = 2) achieved this with abatacept therapy, and under half achieved DAS28/44 remission rates at 6 months (3040%), albeit with half achieving these outcomes by 12 months. This appears to have been driven by the more modest reduction in patient-reported outcomes compared with the more objective indicators of synovitis. Incremental reduction in disease activity over time was observed, with efficient reduction in swollen joint counts and ESR and CRP recorded.
The blinded PDUS assessments provide further evidence of a significant effect on synovial inflammation. A considerable reduction in PDUS was observed within 6 months, and this was maintained over the 2-year period, including following cessation of abatacept. Improvements in GS were more modest, consistent with prior reports of a relative lack of correlation [21, 22] (even at this early stage). Limited radiographic data were available, but suggested no change over the study period, including following abatacept cessation (in line with early use in ACPA-positive disease [11] ).
The open-label nature of the study is a potential weakness, introducing a bias that could have influenced the apparent discrepancy between patient-reported outcomes and SJCs. However, the rapid suppression of inflammation as evidenced by the inflammatory markers (and small deterioration after abatacept cessation) implies a clear biological effect. The absence of a control group means it is not possible to determine whether these improvements would also be seen in a placebo ± synthetic DMARD arm. However, the poor outcomes observed in UA cohorts [8] , together with the selection of poor-prognostic (PD-positive) UA in this study, which in a comparable cohort had an inferior outcome [10] , is suggestive of a benefit over and above placebo. Finally, the distinct genetic associations of ACPA-negative (and -positive) disease means that these data could not necessarily be applied to other ethnic populations.
The clinical, US and radiographic outcomes were maintained in the second year of the study, following cessation of 12 months of abatacept therapy, although half the patients required a synthetic DMARD to maintain this state. Overall, these data suggest that in the vast majority of patients (18/20) , abatacept therapy prevented further progression of disease, but on cessation, additional therapy was indicated to maintain this. The proportion that did not require additional therapy following abatacept cessation might imply the possibility of drug-free disease control; additional follow-up would be able to clarify longer-term outcomes.
In established RA, an association between autoantibody-positive RA and abatacept response has been recently reported in registry data (albeit with relatively marginal differences). Whether this is causal or has a mechanistic basis remains speculative, but the latter relies on the B cell antibody response with enhanced B cell antigen presentation and T-dependent B cell activation. An autoantibody-mediated interaction, however, is not solely required for T cell effector function and development of inflammatory pathology. The anticipated reduction in T cellactivated cytokine production and abrogated activation of other key effector cells, such as dendritic cell, monocyte and synovial fibroblasts (leading to reduced cytokine, chemokine and MMP production, etc.) would be postulated to underlie the benefits we observed in our cohort. It might also be possible that some of our cohort have an as yet undetermined autoantibody status.
In summary, this first report of abatacept therapy in PDpositive ACPA-negative UA provides an initial indication of its ability to improve both clinical disease activity and US parameters of synovial inflammation. These data justify evaluation in a larger, controlled cohort. Further work may also identify biomarkers predictive of greater therapeutic responsiveness.
